SCHEMBL3393182

SCHEMBL3393182

N#Cc1cccc(C[C@H](N)C=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.48
FOLH1 Q04609 1/20 0.47
DPP7 Q9UHL4 3/20 0.45
DPP4 P27487 2/20 0.45
FAP Q12884 1/20 0.45
DPP8 Q6V1X1 1/20 0.45
DPP9 Q86TI2 1/20 0.45
EPHX1 P07099 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43
AKT1 P31749 1/20 0.42
MEP1A Q16819 1/20 0.40
MEP1B Q16820 1/20 0.40
SCN8A Q9UQD0 1/20 0.40
NOS1 P29475 1/20 0.40
PIN1 Q13526 1/20 0.39
VNN1 O95497 2/20 0.39
CYP19A1 P11511 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3392965 1.00 GLA (0.48) GLAFOLH1DPP7DPP4FAP
SCHEMBL21394872 0.81 GLA (0.48) GLAFOLH1DPP7DPP4FAP
SCHEMBL5262783 0.80 GLA (0.57) GLAFOLH1DPP7DPP4FAP
SCHEMBL2265777 0.80 LOXL2 (0.48) DPP7DPP4FAPDPP8DPP9
SCHEMBL14542515 0.80 LOXL2 (0.48) DPP7DPP4FAPDPP8DPP9
SCHEMBL4496028 0.80 GLA (0.57) GLAFOLH1DPP7DPP4FAP
SCHEMBL1972799 0.80 LOXL2 (0.48) DPP7DPP4FAPDPP8DPP9
SCHEMBL3392962 0.79 GLA (0.53) GLAFOLH1DPP7DPP4FAP
SCHEMBL3392958 0.79 GLA (0.53) GLAFOLH1DPP7DPP4FAP
SCHEMBL3393180 0.79 GLA (0.53) GLAFOLH1DPP7DPP4FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060194737-A1 Hepta-, octa-and nonapeptides having antiangiogenic activity HAVIV FORTUNA 2006-08-31 US claimed
US-7067490-B2 Hepta-, Octa-and nonapeptides having antiangiogenic activity ABBOTT LABORATORIES (US) 2006-06-27 US claimed
EP-1232183-B1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LAB (US) 2006-01-18 EP claimed
EP-1451210-A2 HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY Abbott Laboratories (US) 2004-09-01 EP claimed
US-6777535-B1 USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS ABBOTT LABORATORIES 2004-08-17 US claimed
US-6753408-B1 DRUGS USED FOR THERAPY ABBVIE INC. 2004-06-22 US claimed
EP-1421107-A1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY Abbott Laboratories (US) 2004-05-26 EP claimed
US-20030125259-A1 Octa- and nonapeptides having antiangiogenic activity ABBOTT LABORATORIES 2003-07-03 US claimed
US-20030109455-A1 HEPTA-, OCTA-and nonapeptides having antiangiogenic activity ABBVIE INC. 2003-06-12 US claimed
US-20030096758-A1 HEPTA-, OCTA- and nonapeptides having antiangiogenic activity ABBOTT LABORATORIES 2003-05-22 US claimed
WO-2003037268-A2 HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2003-05-08 WO claimed
US-20030050246-A1 Peptides having antiangiogenic activity ABBOTT LABORATORIES 2003-03-13 US claimed
US-20030045477-A1 Peptides having antiangiogenic activity ABBOTT LABORATORIES 2003-03-06 US claimed
WO-2003011896-A1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2003-02-13 WO claimed
EP-1242455-A1 N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY Abbott Laboratories (US) 2002-09-25 EP claimed
EP-1232183-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2002-08-21 EP claimed
WO-2001038347-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
WO-2001038397-A1 N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
EP-2177530-A1 Octapeptide having antiangiogenic activity Abbott Laboratories (US) 2010-04-21 EP disclosed
WO-2001038347-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO disclosed